ABBV — Patent US10537572 Expiration Related to ORILISSA
Sep 1, 2036, 12:00:00 AM UTC
Summary
Patent US10537572 pertaining to the drug ORILISSA, assigned to AbbVie Inc, is set to expire on September 1, 2036. ORILISSA, which contains elagolix, is a GnRH receptor antagonist used for the treatment of endometriosis and uterine fibroids. The expiration of this patent may open the market to generic competitors, potentially impacting AbbVie Inc's revenue from this product.
Company
ABBVIE INC (ABBV)NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.abbvie.comSimilar Events
Patent Expiration for ORILISSA (US11690845)
The patent US11690845 for ORILISSA, which is a GnRH receptor antagonist used in the treatment of endometriosis and other gynecological disorders, is set to expire on August 27, 2040. This expiration may impact AbbVie Inc's market position given the potential for increased generic competition following the patent's lapse.
Patent ExpirationPatent Expiration for ORILISSA (US11690854)
AbbVie Inc's patent US11690854 for ORILISSA, a treatment for heavy menstrual bleeding, is set to expire on April 19, 2038. The patent covers the method of administering the drug in combination with estrogens and progestogens. The expiration of this patent may open the market to generic alternatives, significantly impacting AbbVie's revenue from this product.
Patent ExpirationPatent Expiry for ORILISSA - US11344551
The U.S. patent US11344551 for AbbVie Inc's ORILISSA, which treats heavy menstrual bleeding, is set to expire on March 14, 2034. This expiry may have significant implications for market exclusivity, potentially leading to increased competition from generic versions post-expiry. ORILISSA, administered to patients with or without uterine fibroids, incorporates a specific active ingredient that may diminish in proprietary protection upon the patent's expiration, affecting AbbVie's revenue from this product.
Patent ExpiryExpiration of Patent US11542239 for ORILISSA
The patent US11542239 for ORILISSA, a product containing elagolix sodium, assigned to AbbVie Inc, is set to expire on July 23, 2039. This patent covers the compositions and processes related to elagolix sodium, highlighting its significance in maintaining market exclusivity until the expiration date. Following the expiration, generic competition may emerge, potentially affecting AbbVie Inc's market share and revenue from ORILISSA.
PatentPatent Expiry for ORILISSA (US7419983)
Patent US7419983, which pertains to ORILISSA and is assigned to Neurocrine Biosciences Inc and AbbVie Inc, will expire on July 6, 2029. ORILISSA is a GnRH receptor antagonist used for treating a range of sex-hormone related conditions in both men and women. The expiration of this patent may lead to increased competition in the market, potentially impacting the financial performance of both companies involved as generic alternatives become available.
Patent ExpiryExpiration of Patent US12102637 for ORILISSA
Patent US12102637 for the product ORILISSA, assigned to Neurocrine Biosciences Inc and AbbVie Inc, is set to expire on August 20, 2038. ORILISSA is a pharmaceutical formulation that includes a gonadotropin-releasing hormone (GnRH) antagonist, which plays a role in managing certain hormonal conditions. The expiration of this patent may lead to the entry of generic competitors into the market, potentially impacting the revenue of the assigned companies. Both firms are expected to experience financial ramifications as they adjust to post-patent market conditions.
Patent ExpirationPatent US11117867 Expiration for ORLADEYO
The expiration of Patent US11117867 for ORLADEYO, assigned to Biocryst Pharmaceuticals Inc, is set for November 1, 2039. This patent protects crystalline salts of Compound I, which are integral to the formulation and efficacy of ORLADEYO, a treatment for hereditary angioedema. The expiration could lead to increased competition in the market as generic versions may become available, potentially impacting Biocryst's market share and financial performance significantly.
Patent ExpirationPatent US11926584 Expiration Related to NEXLIZET
Patent US11926584 related to the product NEXLIZET, assigned to Olon Ricerca Bioscience LLC and Esperion Therapeutics Inc., is set to expire on June 19, 2040. This expiration may impact the product's exclusivity in the market, leading to increased competition. NEXLIZET is designed to treat specific health conditions through the active ingredient 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, which is noted for its value in related pharmaceutical compositions and therapeutic methods.
Patent ExpirationPatent US10941118 Expiration Related to OGSIVEO
The patent US10941118 related to the product OGSIVEO, assigned to Pfizer Corp SRL and Springworks Therapeutics Inc, is set to expire on August 9, 2039. The patent encompasses solid state forms and pharmaceutical compositions of hydrobromide salts of Compound 1, which are linked to treatment methods for tumors or cancers. The expiration of this patent may affect the competitive landscape for OGSIVEO, potentially allowing for the introduction of generic alternatives, which could lead to price reductions and impact sales for the companies involved.
Patent